Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
424.00    -15.00 (-3.42%)
Bid:
426.00
Ask:
430.00
Spread: 4.00 (0.939%)
Market Cap: £208.53m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Trading Update

1 Nov 2018 07:00

RNS Number : 9276F
Zotefoams PLC
01 November 2018
 

 

Zotefoams plc

("Zotefoams" or "the Group")

 

Trading Update

 

 

1st November 2018 - Zotefoams, a world leader in cellular materials technology, today provides a trading update for the third quarter ended 30 September 2018.

 

Zotefoams is pleased to report a record third quarter sales performance. Using foreign exchange rates as at 30 September 2018, full-year revenues and profit before tax are now expected to be slightly ahead of consensus market expectations.

 

In the nine months ended 30 September 2018, the Group has recorded:

 

· 16% increase in Group revenues against the comparative period, 18% in constant currency

· 7% growth in Polyolefin foams (72% of Group revenue)

o Improved sales mix

o Additional capacity contributing to 5% higher sales volumes;

· 97% increase in HPP sales (26% of Group revenue)

o Increased product adoption by end-users delivered very strong growth in our ZOTEK® PEBA elastomeric foams used in performance footwear;

o Strong recovery in ZOTEK® F fluoropolymer foams mainly from aviation applications;

o Orders for T-FIT® insulation products, down slightly year-to-date, are more strongly weighted in the final quarter this year, with annual growth in this product range dependent upon timing of shipments in the final quarter;

· MuCell Extrusion (2% of Group revenue)

o Year-to-date sales fell by 21%, excluding the one-off equipment sale in 2017;

o Q3 sales were impacted as a result of our internal restructuring, described in our interim results statement, which absorbed resource;

o MuCell Extrusion is being re-focused to develop the full potential of its technology;

· Capacity expansion programmes in the UK and USA are progressing well, with planned commissioning in 2019, while the announced new capacity in Poland is planned to come on stream in 2020.

 

Commenting on the update David Stirling, Group CEO of Zotefoams, said: 

"We expect 2018 to be another year of substantial progress for the Group: growing revenue, developing our portfolio of opportunities supported by committed capacity investments and enhancing our talent pool. We remain confident about the future prospects of the business."

 

 

- Ends -

 

 

 

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

IFC Advisory (PR)

+44 (0) 203 934 6630

Graham Herring

Miles Nolan

Zach Cohen

 

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. In addition, Zotefoams owns and licenses patented MuCell® microcellular foam technology, developed specifically for extrusion applications, from a base in Massachusetts, USA to customers worldwide.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky and Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT®). A third foam-manufacturing site, in Poland, is planned to begin operations in 2020.

 

www.zotefoams.com

 

AZOTE®, ZOTEK®, T-FIT® are registered trademarks of Zotefoams plc

MuCell® is a registered trademark of Trexel Inc.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTWGGBGUUPRGQG
Date   Source Headline
27th May 20264:06 pmRNSNotification of Transactions of Directors/PDMRs
27th May 20264:00 pmRNSResult of the 2026 Annual General Meeting
27th May 20267:00 amRNSTrading Update
12th May 20267:00 amRNSInvestor Presentation via Investor Meet Company
11th May 20267:00 amRNSNotification of Transactions of Directors/PDMRs
7th May 20267:00 amRNSIssue of Equity
30th Apr 20261:00 pmRNSFinal Dividend Payment Date
27th Apr 20267:00 amRNS2025 Annual Report and Notice of the 2026 AGM
15th Apr 20269:24 amRNSNotification of Transactions of Directors/PDMRs
31st Mar 20266:06 pmRNSHolding(s) in Company
25th Mar 20269:35 amRNSNotification Of Transactions Of Directors/PDMRs
17th Mar 20267:00 amRNSPreliminary Results
17th Mar 20267:00 amRNSPreliminary Results
16th Mar 20261:24 pmRNSNotification Of Transactions Of Directors/PDMRs
16th Mar 20261:24 pmRNSNotification Of Transactions Of Directors/PDMRs
11th Mar 20267:00 amRNSPreliminary results presentation
11th Mar 20267:00 amRNSPreliminary results presentation
13th Feb 20267:00 amRNSNotification Of Transactions Of Directors/PDMRs
27th Jan 20267:00 amRNSChange of Registered Office Address
22nd Jan 20267:00 amRNSTrading Update
15th Jan 20269:57 amRNSNotification Of Transactions Of Directors/PDMRs
15th Dec 20257:00 amRNSNotification Of Transactions Of Directors/PDMRs
18th Nov 202512:39 pmRNSAcquisition of Overseas Konstellation Company S.A.
12th Nov 20254:12 pmRNSNotification Of Transactions Of Directors/PDMRs
4th Nov 20257:00 amRNSTrading Update
24th Oct 20257:00 amRNSNon-Executive Directorate Changes
14th Oct 20252:54 pmRNSNotification Of Transactions Of Directors/PDMRs
9th Oct 20257:00 amRNSNotification Of Transactions Of Directors/PDMRs
30th Sep 20254:25 pmRNSNOTIFICATION OF TRANSACTIONS OF DIRECTORS/PDMRs
22nd Sep 20252:33 pmRNSGroup CFO succession
12th Sep 20255:11 pmRNSNotification Of Transactions Of Directors/PDMR
28th Aug 20257:00 amRNS-RInnovation Initiatives and Executive Appointment
19th Aug 20252:16 pmRNSHolding(s) in Company
14th Aug 20256:19 pmRNSHolding(s) in Company
12th Aug 20252:57 pmRNSNotification Of Transactions Of Directors/PDMR
8th Aug 20257:00 amRNSHolding(s) in Company
7th Aug 202512:14 pmRNSHolding(s) in Company
5th Aug 20257:01 amRNSJoint Venture Agreement and Executive Appointment
5th Aug 20257:00 amRNSInterim Results
29th Jul 202511:01 amRNSInvestor Presentation via Investor Meet Company
14th Jul 20252:51 pmRNSNotification Of Transactions Of Directors/PDMRs
12th Jun 20252:41 pmRNSNotification of Transactions of Directors/PDMRs
10th Jun 20254:13 pmRNSNotification Of Transactions Of Directors/PDMRs
22nd May 202512:30 pmRNSResult of the 2025 Annual General Meeting
22nd May 20257:00 amRNSTrading Update
13th May 202512:05 pmRNSNotification Of Transactions Of Directors/PDMRs
1st May 20257:00 amRNSNotification Of Transactions Of Directors/PDMRs
30th Apr 20257:00 amRNSGroup CFO succession
24th Apr 20257:00 amRNSNotification Of Transactions Of Directors/PDMRs
22nd Apr 20257:00 amRNS2024 Annual Report & Notice of 2025 AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.